ClinicalTrials.gg
CompletedNCT03930615Updated Aug 22, 2024Results posted

Extension of Letermovir (LET) From Day 100 to Day 200 Post-transplant for the Prevention of Cytomegalovirus (CMV) Infection in Hematopoietic Stem Cell Transplant (HSCT) Participants (MK-8228-040)

A Phase 3 interventional study of Letermovir and Placebo in Cytomegalovirus Infection, sponsored by Merck Sharp & Dohme LLC. Completed at 32 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-08-22.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
220
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 17 studies testing letermovir in Cytomegalovirus Infections — 7 open to participants now, 8 under way, 3 of them phase 3. letermovir · Cytomegalovirus Infections.

Enrollment
3rd of 17
220 · median 80
Started
2019
with 3 others
Phase 3
6 of 17
3 open now
Registered
2nd of 17
by date
Lead sponsor
4 of 17
Merck Sharp & Dohme LLC

Among the 17 studies testing letermovir in Cytomegalovirus Infections, this one is the 3rd largest by enrollment, is one of 4 that started in 2019, is one of 6 in phase 3, and was the 2nd registered.

Cytomegalovirus Infections

370 studies on the registry are indexed under Cytomegalovirus Infections; 57 are open to participants now.

Browse Cytomegalovirus Infections studies →

Open to participants now

7 of the 17 studies testing letermovir in Cytomegalovirus Infections are open now, in 4 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About letermovir

letermovir: first FDA approval 2017 (PREVYMIS), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 35 Cytomegalovirus Infections studies recruiting now, 20 (57%) set no upper age limit and 13 (37%) stop at 75 or younger; 19 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies testing letermovir in Cytomegalovirus Infections, or all of them as a file.
02

Study summary

The purpose of this study was to evaluate the safety and efficacy of letermovir (LET) versus placebo when cytomegalovirus (CMV) prophylaxis was extended from 100 days to 200 days post-transplant in CMV seropositive participants who received an allogenic hematopoietic stem cell transplant (HSCT). It was hypothesized that LET is superior to placebo in the prevention of clinically-significant CMV infection when LET prophylaxis is extended from 100 to 200 days.

03

Conditions studied

  • Cytomegalovirus Infection
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • have documented positive CMV serostatus (CMV immunoglobulin G [IgG] seropositive) for recipient (R+) at the time of transplant
  • has a history of HSCT (bone marrow, peripheral blood stem cell, or cord blood transplant) within \~100 days prior to randomization
  • has undetectable CMV deoxyribonucleic acid (DNA) or detectable/not quantifiable CMV DNA from a plasma sample collected within 14 days prior to randomization
  • has received LET as primary prophylaxis that started within 28 days of HSCT and continued through Week 14 post-transplant (± 1 week) prior to randomization
  • is at high risk of CMV disease, defined as meeting one or more of the following criteria:
  • has a related donor with at least 1 mismatch at 1 of the specified 3 human leukocyte antigen (HLA) gene loci (HLA-A, B, or DR)
  • has an unrelated donor with at least one mismatch at one of the specified four HLA gene loci (HLA-A, B, C, and DRB1)
  • has a haploidentical donor
  • has umbilical cord blood as the stem-cell source
  • has ex-vivo T-cell-depleted grafts
  • has received anti-thymocyte globulin
  • has received alemtuzumab
  • has (GVHD) or other conditions, requiring the use of systemic prednisone (or equivalent) at a dose of ≥1 mg/kg of body weight per day within 6 weeks of randomization
  • for female participants, is not pregnant or breastfeeding, and is either not a woman of (WOCBP) or is a WOBCP who agrees to use acceptable during the treatment period and for ≥28 days after the last dose of study drug.

Exclusion criteria

Exclusion Criteria:

  • has a history of CMV end-organ disease or preemptive treatment therapy for CMV after prior to randomization
  • has a history of >14 days total of LET interruption during the first 100 days post-transplant prior to randomization
  • has suspected or known to active or inactive ingredients of LET formulations
  • has severe hepatic insufficiency defined as Class C within 14 days prior to randomization.
  • has serum (AST) or alanine aminotransferase (ALT) >5× the (ULN) within 14 days prior to randomization
  • has end-stage renal impairment with a less than 10 mL/min, as calculated by the Cockcroft-Gault equation using serum creatinine within 14 days prior to randomization
  • has both moderate hepatic insufficiency AND moderate-to-severe renal insufficiency
  • has an uncontrolled infection on the day of enrollment
  • requires mechanical ventilation or is hemodynamically unstable at the time of enrollment
  • has a documented positive result for a antibody (HIV-Ab) test at any time prior to screening, or for virus antibody (HCV-Ab) with detectable HCV ribonucleic acid (RNA), or surface antigen (HBsAg) within 6 months prior to screening.
  • has active solid tumor with the exception of localized basal cell or squamous cell skin cancer or the condition under treatment (eg, lymphomas)
  • has received cidofovir or CMV immunoglobulin with 30 days prior to screening
  • is currently participating or has participated in a study with an unapproved compound, monoclonal antibody, or device within 28 days or 5× half-life of the investigational compound or monoclonal antibody, whichever is longer, of initial dosing in this study
  • has previously participated in this study or any other study involving LET, or is currently participating in any study involving administration of a CMV vaccine or another CMV investigational agent, or is planning to participate in a study of a CMV vaccine or another CMV investigational agent during the course of this study
  • is pregnant or expecting to conceive, is breastfeeding, or plans to breastfeed from the time of consent through 28 days after the last dose of study therapy
  • is expecting to donate eggs starting from the time of consent through 28 days after the last dose of study therapy
  • has drug or alcohol abuse within 12 months of screening that may interfere with participant treatment, assessment, or compliance with the protocol as assessed by the investigator
  • has a history or current evidence of any condition, therapy, lab abnormality, or other circumstance that might confound the results of the study, interfere with the participant's participation for the full duration of the study, or would be put at undue risk as judged by the investigator, such that it is not in the best interest of the participant to participate in this study
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
220 participants (actual)

Study arms

  • Experimental
    Letermovir

    Participants who received HSCT transplant and 100 days of LET prophylaxis were randomized to an additional 100 days of LET (480 mg once daily alone or 240 mg once daily for participants on cyclosporin A) treatment.

    Drug: Letermovir

  • Placebo comparator
    Placebo

    Participants who received HSCT transplant and 100 days of LET prophylaxis were randomized to an additional 100 days of placebo treatment.

    Drug: Placebo

Interventions

  • LET tablet or intravenous infusion at a total daily dose of 240 mg (when given with cyclosporin A) or 480 mg (when given alone).

    Also known as: PREVYMIS™, MK-8228

  • DrugPlacebo

    Placebo was administered as tablets matched to LET or as inactive (saline or dextrose) intravenous infusion.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Clinically Significant CMV Infection From Week 14 (~100 Days) Post-transplant Through Week 28 (~200 Days) Post-transplant

    Clinically significant CMV infection is either the onset of probable or proven CMV end-organ disease or initiation of anti-CMV preemptive therapy (PET) with approved anti-CMV agents (ganciclovir, valganciclovir, foscarnet, and/or cidofovir) based on documented CMV viremia and the clinical condition of the participant. Missing values were handled by the observed failure (OF) approach where failure was defined as all participants who develop clinically significant CMV infection or discontinue prematurely from the study with CMV viremia from week 14 (\~100 days) through week 28 post-transplant. It was hypothesized that LET is superior to placebo in the prevention of clinically significant CMV infection when LET prophylaxis is extended from 100 to 200 days.

    Time frame: From Week 14 post-transplant to Week 28 post-transplant (approximately 14 weeks)

Secondary outcomes

  1. Percentage of Participants Experiencing ≥1 Adverse Events (AEs) From Week 14 (~100 Days) Post-transplant Through Week 28 (~200 Days) Post-transplant

    An adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.

    Time frame: From Week 14 post-transplant to Week 28 post-transplant (approximately 14 weeks)

  2. Percentage of Participants Withdrawing From Study Drug Due to an AE From Week 14 (~100 Days) Post-transplant Through Week 28 (~200 Days) Post-transplant

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.

    Time frame: From Week 14 post-transplant to Week 28 post-transplant (approximately 14 weeks)

  3. Percentage of Participants With Clinically Significant CMV Infection From Week 14 Post-transplant Through Week 38 Post-transplant

    Clinically significant CMV infection is either the onset of probable or proven CMV end-organ disease or initiation of anti-CMV PET with approved anti-CMV agents (ganciclovir, valganciclovir, foscarnet, and/or cidofovir) based on documented CMV viremia and the clinical condition of the participant. Missing values were handled by the OF approach where failure was defined as all participants who develop clinically significant CMV infection or discontinue prematurely from the study with CMV viremia from week 14 (\~100 days) through week 38 post-transplant.

    Time frame: From Week 14 post-transplant to Week 38 post-transplant (approximately 24 weeks)

  4. Percentage of Participants With Clinically Significant CMV Infection From Week 14 Post-transplant Through Week 48 Post-transplant

    Clinically significant CMV infection is either the onset of probable or proven CMV end-organ disease or initiation of anti-CMV PET with approved anti-CMV agents (ganciclovir, valganciclovir, foscarnet, and/or cidofovir) based on documented CMV viremia and the clinical condition of the participant. Missing values were handled by the OF approach where failure was defined as all participants who develop clinically significant CMV infection or discontinue prematurely from the study with CMV viremia from week 14 (\~100 days) through week 48 post-transplant.

    Time frame: From Week 14 post-transplant to Week 48 post-transplant (approximately 34 weeks)

  5. Time to Onset of Clinically Significant CMV Infection From Week 14 Post-transplant to Week 28 Post-transplant

    Clinically significant CMV infection is either the onset of probable or proven CMV end-organ disease or initiation of anti-CMV PET with approved anti-CMV agents (ganciclovir, valganciclovir, foscarnet, and/or cidofovir) based on documented CMV viremia and the clinical condition of the participant. Time to onset of clinically significant CMV infection is the elapsed time from transplant to the onset of CMV end-organ disease or to the initiation of anti-CMV PET. Time to onset was determined from the Kaplan-Meier method for censored data.

    Time frame: From Week 14 post-transplant to Week 28 post-transplant (approximately 14 weeks)

  6. Time to Onset of Clinically Significant CMV Infection From Week 14 Post-transplant to Week 48 Post-transplant

    Clinically significant CMV infection is either the onset of probable or proven CMV end-organ disease or initiation of anti-CMV PET with approved anti-CMV agents (ganciclovir, valganciclovir, foscarnet, and/or cidofovir) based on documented CMV viremia and the clinical condition of the participant. Time to onset of clinically significant CMV infection is the elapsed time from transplant to the onset of CMV end-organ disease or to the initiation of anti-CMV PET. Time to onset was determined from the Kaplan-Meier method for censored data.

    Time frame: From Week 14 post-transplant to Week 48 post-transplant (approximately 34 weeks)

  7. Percentage of Participants With CMV Viremia Who Started PET From Week 14 Post-transplant to Week 28 Post-transplant

    The percentage of participants with CMV viremia who initiated PET of anti-CMV agents (ganciclovir, valganciclovir, foscarnet, and/or cidofovir) was determined. Missing values were handled with the OF approach, where failure was defined as all participants who develop clinically significant CMV infection or discontinue prematurely from the study with CMV viremia from week 14 through week 28 post-transplant.

    Time frame: From Week 14 post-transplant to Week 28 post-transplant (approximately 14 weeks)

  8. Percentage of Participants With CMV Viremia Who Started PET From Week 14 Post-transplant to Week 48 Post-transplant

    The percentage of participants with CMV viremia who initiated PET of anti-CMV agents (ganciclovir, valganciclovir, foscarnet, and/or cidofovir) was determined. Missing values were handled with the OF approach, where failure was defined as all participants who develop clinically significant CMV infection or discontinue prematurely from the study with CMV viremia from week 14 through week 48 post-transplant.

    Time frame: From Week 14 post-transplant to Week 48 post-transplant (approximately 34 weeks)

  9. Percentage of Participants With All-cause Mortality From Week 14 Post-transplant to Week 28 Post-transplant

    The percentage of participants who died due to any cause (all-cause mortality) from Week 14 to Week 28 was determined.

    Time frame: From Week 14 post-transplant to Week 28 post-transplant (approximately 14 weeks)

  10. Percentage of Participants With All-cause Mortality From Week 14 Post-transplant to Week 48 Post-transplant

    The percentage of participants who died due to any cause (all-cause mortality) from Week 14 to Week 48 was determined.

    Time frame: From Week 14 post-transplant to Week 48 post-transplant (approximately 34 weeks)

  11. Time to All-cause Mortality From Week 14 Post-transplant to Week 28 Post-transplant

    Time to all-cause mortality is the time elapsed after Week 14 post-transplant and death due to any cause, and was determined from the Kaplan-Meier method for censored data.

    Time frame: From Week 14 post-transplant to Week 28 post-transplant (approximately 14 weeks)

  12. Time to All-cause Mortality From Week 14 Post-transplant to Week 48 Post-transplant

    Time to all-cause mortality is the time elapsed after Week 14 post-transplant and death due to any cause, and was determined from the Kaplan-Meier method for censored data.

    Time frame: From Week 14 post-transplant to Week 48 post-transplant (approximately 34 weeks)

07

Results

Posted Nov 1, 2022

Participant flow

Cytomegalovirus (CMV)-seropositive recipients (R+) of a hematopoietic stem cell transplant (HSCT) who had received letermovir (LET) prophylaxis through Week 14 (\~100 days) post-transplant and were at high risk for CMV infection and/or disease were enrolled in this study.

Participant flow — Overall Study
MilestoneLetermovirPlacebo
Started14575
Treated14474
Completed11863
Not completed2712
Withdrew: Death93
Withdrew: Lost to follow-up12
Withdrew: Physician decision34
Withdrew: Withdrawal by subject132
Withdrew: Not treated11

Outcome measures

PrimaryPercentage of Participants With Clinically Significant CMV Infection From Week 14 (~100 Days) Post-transplant Through Week 28 (~200 Days) Post-transplant

Clinically significant CMV infection is either the onset of probable or proven CMV end-organ disease or initiation of anti-CMV preemptive therapy (PET) with approved anti-CMV agents (ganciclovir, valganciclovir, foscarnet, and/or cidofovir) based on documented CMV viremia and the clinical condition of the participant. Missing values were handled by the observed failure (OF) approach where failure was defined as all participants who develop clinically significant CMV infection or discontinue prematurely from the study with CMV viremia from week 14 (\~100 days) through week 28 post-transplant. It was hypothesized that LET is superior to placebo in the prevention of clinically significant CMV infection when LET prophylaxis is extended from 100 to 200 days.

Time frame:
From Week 14 post-transplant to Week 28 post-transplant (approximately 14 weeks)
Reported as:
Number · Percentage of participants
Percentage of Participants With Clinically Significant CMV Infection From Week 14 (~100 Days) Post-transplant Through Week 28 (~200 Days) Post-transplant
Percentage of participantsLetermovirPlacebo
Percentage of Participants With Clinically Significant CMV Infection From Week 14 (~100 Days) Post-transplant Through Week 28 (~200 Days) Post-transplant2.818.9
Statistical analysis
  • Letermovir vs Placebo · Mantel Haenszel · p = 0.0005 (A one-sided p-value ≤0.0249 was used for declaring statistical significance) · Treatment difference: -16.1 · 95% CI -25.8 to -6.5Letermovir minus placebo
SecondaryPercentage of Participants Experiencing ≥1 Adverse Events (AEs) From Week 14 (~100 Days) Post-transplant Through Week 28 (~200 Days) Post-transplant

An adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.

Time frame:
From Week 14 post-transplant to Week 28 post-transplant (approximately 14 weeks)
Reported as:
Number · Percentage of participants
Percentage of Participants Experiencing ≥1 Adverse Events (AEs) From Week 14 (~100 Days) Post-transplant Through Week 28 (~200 Days) Post-transplant
Percentage of participantsLetermovirPlacebo
Percentage of Participants Experiencing ≥1 Adverse Events (AEs) From Week 14 (~100 Days) Post-transplant Through Week 28 (~200 Days) Post-transplant88.993.2
Statistical analysis
  • Letermovir vs Placebo · Difference in percentage: -4.4 · 95% CI -11.8 to 4.7Letermovir minus Placebo
SecondaryPercentage of Participants Withdrawing From Study Drug Due to an AE From Week 14 (~100 Days) Post-transplant Through Week 28 (~200 Days) Post-transplant

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.

Time frame:
From Week 14 post-transplant to Week 28 post-transplant (approximately 14 weeks)
Reported as:
Number · Percentage of participants
Percentage of Participants Withdrawing From Study Drug Due to an AE From Week 14 (~100 Days) Post-transplant Through Week 28 (~200 Days) Post-transplant
Percentage of participantsLetermovirPlacebo
Percentage of Participants Withdrawing From Study Drug Due to an AE From Week 14 (~100 Days) Post-transplant Through Week 28 (~200 Days) Post-transplant4.91.4
Statistical analysis
  • Letermovir vs Placebo · Difference in percentage: 3.5 · 95% CI -2.7 to 8.6Letermovir minus Placebo
SecondaryPercentage of Participants With Clinically Significant CMV Infection From Week 14 Post-transplant Through Week 38 Post-transplant

Clinically significant CMV infection is either the onset of probable or proven CMV end-organ disease or initiation of anti-CMV PET with approved anti-CMV agents (ganciclovir, valganciclovir, foscarnet, and/or cidofovir) based on documented CMV viremia and the clinical condition of the participant. Missing values were handled by the OF approach where failure was defined as all participants who develop clinically significant CMV infection or discontinue prematurely from the study with CMV viremia from week 14 (\~100 days) through week 38 post-transplant.

Time frame:
From Week 14 post-transplant to Week 38 post-transplant (approximately 24 weeks)
Reported as:
Number · Percentage of participants
Percentage of Participants With Clinically Significant CMV Infection From Week 14 Post-transplant Through Week 38 Post-transplant
Percentage of participantsLetermovirPlacebo
Percentage of Participants With Clinically Significant CMV Infection From Week 14 Post-transplant Through Week 38 Post-transplant14.620.3
Statistical analysis
  • Letermovir vs Placebo · Mantel Haenszel · p = 0.1591 · Treatment difference: -5.7 · 95% CI -16.8 to 5.4Letermovir minus placebo
SecondaryPercentage of Participants With Clinically Significant CMV Infection From Week 14 Post-transplant Through Week 48 Post-transplant

Clinically significant CMV infection is either the onset of probable or proven CMV end-organ disease or initiation of anti-CMV PET with approved anti-CMV agents (ganciclovir, valganciclovir, foscarnet, and/or cidofovir) based on documented CMV viremia and the clinical condition of the participant. Missing values were handled by the OF approach where failure was defined as all participants who develop clinically significant CMV infection or discontinue prematurely from the study with CMV viremia from week 14 (\~100 days) through week 48 post-transplant.

Time frame:
From Week 14 post-transplant to Week 48 post-transplant (approximately 34 weeks)
Reported as:
Number · Percentage of participants
Percentage of Participants With Clinically Significant CMV Infection From Week 14 Post-transplant Through Week 48 Post-transplant
Percentage of participantsLetermovirPlacebo
Percentage of Participants With Clinically Significant CMV Infection From Week 14 Post-transplant Through Week 48 Post-transplant14.620.3
Statistical analysis
  • Letermovir vs Placebo · Mantel Haenszel · p = 0.1591 · Treatment difference: -5.7 · 95% CI -16.8 to 5.4Letermovir minus placebo
SecondaryTime to Onset of Clinically Significant CMV Infection From Week 14 Post-transplant to Week 28 Post-transplant

Clinically significant CMV infection is either the onset of probable or proven CMV end-organ disease or initiation of anti-CMV PET with approved anti-CMV agents (ganciclovir, valganciclovir, foscarnet, and/or cidofovir) based on documented CMV viremia and the clinical condition of the participant. Time to onset of clinically significant CMV infection is the elapsed time from transplant to the onset of CMV end-organ disease or to the initiation of anti-CMV PET. Time to onset was determined from the Kaplan-Meier method for censored data.

Time frame:
From Week 14 post-transplant to Week 28 post-transplant (approximately 14 weeks)
Reported as:
Median · Days
Time to Onset of Clinically Significant CMV Infection From Week 14 Post-transplant to Week 28 Post-transplant
DaysLetermovirPlacebo
Time to Onset of Clinically Significant CMV Infection From Week 14 Post-transplant to Week 28 Post-transplantNA (NA to NA)NA (NA to NA)
SecondaryTime to Onset of Clinically Significant CMV Infection From Week 14 Post-transplant to Week 48 Post-transplant

Clinically significant CMV infection is either the onset of probable or proven CMV end-organ disease or initiation of anti-CMV PET with approved anti-CMV agents (ganciclovir, valganciclovir, foscarnet, and/or cidofovir) based on documented CMV viremia and the clinical condition of the participant. Time to onset of clinically significant CMV infection is the elapsed time from transplant to the onset of CMV end-organ disease or to the initiation of anti-CMV PET. Time to onset was determined from the Kaplan-Meier method for censored data.

Time frame:
From Week 14 post-transplant to Week 48 post-transplant (approximately 34 weeks)
Reported as:
Median · Days
Time to Onset of Clinically Significant CMV Infection From Week 14 Post-transplant to Week 48 Post-transplant
DaysLetermovirPlacebo
Time to Onset of Clinically Significant CMV Infection From Week 14 Post-transplant to Week 48 Post-transplantNA (NA to NA)NA (NA to NA)
SecondaryPercentage of Participants With CMV Viremia Who Started PET From Week 14 Post-transplant to Week 28 Post-transplant

The percentage of participants with CMV viremia who initiated PET of anti-CMV agents (ganciclovir, valganciclovir, foscarnet, and/or cidofovir) was determined. Missing values were handled with the OF approach, where failure was defined as all participants who develop clinically significant CMV infection or discontinue prematurely from the study with CMV viremia from week 14 through week 28 post-transplant.

Time frame:
From Week 14 post-transplant to Week 28 post-transplant (approximately 14 weeks)
Reported as:
Number · Percentage of participants
Percentage of Participants With CMV Viremia Who Started PET From Week 14 Post-transplant to Week 28 Post-transplant
Percentage of participantsLetermovirPlacebo
Percentage of Participants With CMV Viremia Who Started PET From Week 14 Post-transplant to Week 28 Post-transplant2.116.2
Statistical analysis
  • Letermovir vs Placebo · Mantel Haenszel · p = 0.0012 · Treatment difference: -14.1 · 95% CI -23.3 to -5.0Letermovir minus placebo
SecondaryPercentage of Participants With CMV Viremia Who Started PET From Week 14 Post-transplant to Week 48 Post-transplant

The percentage of participants with CMV viremia who initiated PET of anti-CMV agents (ganciclovir, valganciclovir, foscarnet, and/or cidofovir) was determined. Missing values were handled with the OF approach, where failure was defined as all participants who develop clinically significant CMV infection or discontinue prematurely from the study with CMV viremia from week 14 through week 48 post-transplant.

Time frame:
From Week 14 post-transplant to Week 48 post-transplant (approximately 34 weeks)
Reported as:
Number · Percentage of participants
Percentage of Participants With CMV Viremia Who Started PET From Week 14 Post-transplant to Week 48 Post-transplant
Percentage of participantsLetermovirPlacebo
Percentage of Participants With CMV Viremia Who Started PET From Week 14 Post-transplant to Week 48 Post-transplant13.218.9
Statistical analysis
  • Letermovir vs Placebo · Mantel Haenszel · p = 0.1494 · Treatment difference: -5.7 · 95% CI -16.5 to 5.1Letermovir minus placebo
SecondaryPercentage of Participants With All-cause Mortality From Week 14 Post-transplant to Week 28 Post-transplant

The percentage of participants who died due to any cause (all-cause mortality) from Week 14 to Week 28 was determined.

Time frame:
From Week 14 post-transplant to Week 28 post-transplant (approximately 14 weeks)
Reported as:
Number · Percentage of participants
Percentage of Participants With All-cause Mortality From Week 14 Post-transplant to Week 28 Post-transplant
Percentage of participantsLetermovirPlacebo
Percentage of Participants With All-cause Mortality From Week 14 Post-transplant to Week 28 Post-transplant2.11.4
Statistical analysis
  • Letermovir vs Placebo · Mantel Haenszel · p = 0.6244 · Treatment difference: 0.7 · 95% CI -3.8 to 5.3Letermovir minus placebo
SecondaryPercentage of Participants With All-cause Mortality From Week 14 Post-transplant to Week 48 Post-transplant

The percentage of participants who died due to any cause (all-cause mortality) from Week 14 to Week 48 was determined.

Time frame:
From Week 14 post-transplant to Week 48 post-transplant (approximately 34 weeks)
Reported as:
Number · Percentage of participants
Percentage of Participants With All-cause Mortality From Week 14 Post-transplant to Week 48 Post-transplant
Percentage of participantsLetermovirPlacebo
Percentage of Participants With All-cause Mortality From Week 14 Post-transplant to Week 48 Post-transplant8.38.1
Statistical analysis
  • Letermovir vs Placebo · Mantel Haenszel · p = 0.5264 · Treatment difference: 0.3 · 95% CI -7.9 to 8.4Letermovir minus placebo
SecondaryTime to All-cause Mortality From Week 14 Post-transplant to Week 28 Post-transplant

Time to all-cause mortality is the time elapsed after Week 14 post-transplant and death due to any cause, and was determined from the Kaplan-Meier method for censored data.

Time frame:
From Week 14 post-transplant to Week 28 post-transplant (approximately 14 weeks)
Reported as:
Median · Days
Time to All-cause Mortality From Week 14 Post-transplant to Week 28 Post-transplant
DaysLetermovirPlacebo
Time to All-cause Mortality From Week 14 Post-transplant to Week 28 Post-transplantNA (NA to NA)NA (NA to NA)
SecondaryTime to All-cause Mortality From Week 14 Post-transplant to Week 48 Post-transplant

Time to all-cause mortality is the time elapsed after Week 14 post-transplant and death due to any cause, and was determined from the Kaplan-Meier method for censored data.

Time frame:
From Week 14 post-transplant to Week 48 post-transplant (approximately 34 weeks)
Reported as:
Median · Days
Time to All-cause Mortality From Week 14 Post-transplant to Week 48 Post-transplant
DaysLetermovirPlacebo
Time to All-cause Mortality From Week 14 Post-transplant to Week 48 Post-transplantNA (NA to NA)NA (NA to NA)

Adverse events

Collected over All-cause mortality: From 14 weeks post-transplant up to 48 weeks post-transplant (approximately 34 weeks); adverse events (AEs) and serious AEs (SAEs): From 14 weeks post-transplant up to 30 weeks post-transplant (approximately 16 weeks).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Letermovir16/145 (11%)49/144 (34%)100/144 (69.4%)
Placebo8/75 (10.7%)27/74 (36.5%)58/74 (78.4%)
Most frequent serious events
Showing 10 of 83
Most frequent serious events
EventLetermovirPlacebo
Graft versus host diseaseImmune system disorders9/1446/74
PneumoniaInfections and infestations4/1445/74
Acute myeloid leukaemia recurrentNeoplasms benign, malignant and unspecified (incl cysts and polyps)8/1443/74
PyrexiaGeneral disorders4/1441/74
NeutropeniaBlood and lymphatic system disorders0/1442/74
Thrombotic microangiopathyBlood and lymphatic system disorders0/1442/74
Anal abscessInfections and infestations0/1442/74
Bronchopulmonary aspergillosisInfections and infestations0/1442/74
COVID-19 pneumoniaInfections and infestations0/1442/74
SepsisInfections and infestations2/1442/74
Most frequent other events
Showing 10 of 23
Most frequent other events
EventLetermovirPlacebo
Graft versus host diseaseImmune system disorders45/14422/74
NauseaGastrointestinal disorders17/14415/74
DiarrhoeaGastrointestinal disorders16/14411/74
Decreased appetiteMetabolism and nutrition disorders6/14411/74
Oedema peripheralGeneral disorders12/1449/74
PyrexiaGeneral disorders12/1449/74
CoughRespiratory, thoracic and mediastinal disorders8/1449/74
RashSkin and subcutaneous tissue disorders9/1448/74
Oropharyngeal painRespiratory, thoracic and mediastinal disorders9/1446/74
PruritusSkin and subcutaneous tissue disorders11/1442/74

Baseline characteristics

Treated participants

Age, Continuous
Age, Continuous(Years)LetermovirPlaceboTotal
Mean51.9 ± 14.352.7 ± 12.952.2 ± 13.8
Sex: Female, Male
Sex: Female, Male(Participants)LetermovirPlaceboTotal
Female523183
Male9243135
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)LetermovirPlaceboTotal
Hispanic or Latino13821
Not Hispanic or Latino10653159
Unknown or Not Reported251338
Race (NIH/OMB)
Race (NIH/OMB)(Participants)LetermovirPlaceboTotal
American Indian or Alaska Native000
Asian16824
Native Hawaiian or Other Pacific Islander202
Black or African American314
White11360173
More than one race213
Unknown or Not Reported8412
Donor Stratum
Donor Stratum(Participants)LetermovirPlaceboTotal
Haploidentical452267
Non-haploidentical9952151
08

Study locations

32 sites
  • City of Hope National Medical Center ( Site 0158)
    Duarte, California 91010, United States
  • University of California Davis Medical Center ( Site 0156)
    Sacramento, California 95817, United States
  • University of Miami, Sylvester Comprehensive Cancer Center ( Site 0160)
    Miami, Florida 33136, United States
  • Indiana Blood and Marrow Transplantation ( Site 0175)
    Indianapolis, Indiana 46237, United States
  • Brigham & Women's Hospital ( Site 0161)
    Boston, Massachusetts 02115, United States
  • John Theurer Cancer Center at Hackensack University Med Ctr ( Site 0174)
    Hackensack, New Jersey 07601, United States
  • Memorial Sloan Kettering Cancer Center ( Site 0164)
    New York, New York 10065, United States
  • Duke University Medical Center ( Site 0169)
    Durham, North Carolina 27710, United States
  • The University of Texas MD Anderson Cancer Center ( Site 0154)
    Houston, Texas 77030, United States
  • Fred Hutchinson Cancer Research Center ( Site 0152)
    Seattle, Washington 98109, United States
  • Centre Hospitalier Universitaire Dupuytren ( Site 0182)
    Limoges, Haute-Vienne 87042, France
  • Hopital Saint Eloi ( Site 0031)
    Montpellier, Herault 34295, France
  • Centre Hopitalier Lyon Sud ( Site 0039)
    Pierre Benite, Rhone 69495, France
  • CHU Henri Mondor ( Site 0032)
    Creteil, Val-de-Marne 94110, France
  • Institut Gustave Roussy ( Site 0038)
    Villejuif, Val-de-Marne 94805, France
  • CHU Hopital Saint Antoine ( Site 0036)
    Paris, 75012, France
  • Universitaetsklinikum Heidelberg-Medizinische Klinik V ( Site 0042)
    Heidelberg, Baden-Wurttemberg 69120, Germany
  • Universitaetsklinik Koeln ( Site 0041)
    Koeln, Nordrhein-Westfalen 50937, Germany
  • Universitaetsklinikum Muenster ( Site 0043)
    Muenster, Nordrhein-Westfalen 48149, Germany
  • ASST Spedali Civili di Brescia ( Site 0052)
    Brescia, Lombardia 25123, Italy
  • IRCCS Ospedale San Raffaele ( Site 0051)
    Milano, 20132, Italy
  • Fondazione PTV Policlinico Tor Vergata ( Site 0054)
    Roma, 00133, Italy
  • Policlinico Umberto I ( Site 0056)
    Roma, 00161, Italy
  • Policlinico Universitario Agostino Gemelli ( Site 0055)
    Roma, 00168, Italy
  • Jichi Medical University Hospital ( Site 0123)
    Shimotsuke, Tochigi 329-0498, Japan
  • Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital ( Site 0121)
    Hiroshima, 730-8619, Japan
  • National Hospital Organization Kumamoto Medical Center ( Site 0122)
    Kumamoto, 860-0008, Japan
  • Queen Elizabeth University Hospital [Glasgow, UK] ( Site 0096)
    Glasgow, Glasgow City G51 4TF, United Kingdom
  • 1Kings College Hospital ( Site 0091)
    London, London, City Of SE5 9RS, United Kingdom
  • UCL Cancer Institute ( Site 0093)
    London, London, City Of WC1E 6BT, United Kingdom
  • Manchester Royal Infirmary ( Site 0097)
    Manchester, M13 9WL, United Kingdom
  • Freeman Hospital Newcastle upon Tyne Foundation NHS Trust ( Site 0092)
    Newcastle upon Tyne, NE7 7DN, United Kingdom
09

References and documents

Publications

  • Russo D, Schmitt M, Pilorge S, Stelljes M, Kawakita T, Teal VL, Haber B, Bopp C, Dadwal SS, Badshah C. Efficacy and safety of extended duration letermovir prophylaxis in recipients of haematopoietic stem-cell transplantation at risk of cytomegalovirus infection: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Haematol. 2024 Feb;11(2):e127-e135. doi: 10.1016/S2352-3026(23)00344-7. Epub 2023 Dec 21. PubMed 38142695 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · engagezone.msd.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2019 to primary completion in Oct 2021, 28 months.

Results were first posted in Nov 2022, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 26, 2019
First posted
Apr 29, 2019
StartActual
Jun 21, 2019
Primary completionActual
Oct 27, 2021
CompletionActual
Mar 16, 2022
Results first posted
Nov 1, 2022
Last update
Aug 22, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 22, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03930615
Responsible party
Sponsor
First posted
Apr 29, 2019
Start date
Jun 21, 2019
Primary completion
Oct 27, 2021
Completion
Mar 16, 2022
Results posted
Nov 1, 2022
Last update
Aug 22, 2024

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Letermovir

Start the discussion